SpringWorks Therapeutics Inc at Goldman Sachs Healthcare Conference Transcript
All right. Well, thanks, everyone, for joining us here. And thanks especially to Saqib Islam, CEO; and Badreddin Edris, COO for SpringWorks Therapeutics.
Questions & Answers
Maybe just to kick us off this morning. Could you just provide a brief overview of the company, with a particular focus on what you see as key value drivers over the next 12 to 24 months?
Sure. Thanks, and thanks for having us once again at your conference, Corrinne. I think we are in a very fortunate position of having at least 2 very meaningful drivers over the next 12, 24 months where you'll start off with nirogacestat for desmoid tumors, where we have submitted our Phase III data, where we are looking to have an approval this year in a disease where there is no approved therapy.
Following that, we've got data in our next drug,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
